Glutamate excitotoxicity: Potential therapeutic target for ischemic stroke

Biomed Pharmacother. 2022 Jul:151:113125. doi: 10.1016/j.biopha.2022.113125. Epub 2022 May 24.

Abstract

Glutamate-mediated excitotoxicity is an important mechanism leading to post ischemic stroke damage. After acute stroke, the sudden reduction in cerebral blood flow is most initially followed by ion transport protein dysfunction and disruption of ion homeostasis, which in turn leads to impaired glutamate release, reuptake, and excessive N-methyl-D-aspartate receptor (NMDAR) activation, promoting neuronal death. Despite extensive evidence from preclinical studies suggesting that excessive NMDAR stimulation during ischemic stroke is a central step in post-stroke damage, NMDAR blockers have failed to translate into clinical stroke treatment. Current treatment options for stroke are very limited, and there is therefore a great need to develop new targets for neuroprotective therapeutic agents in ischemic stroke to extend the therapeutic time window. In this review, we highlight recent findings on glutamate release, reuptake mechanisms, NMDAR and its downstream cellular signaling pathways in post-ischemic stroke damage, and review the pathological changes in each link to help develop viable new therapeutic targets. We then also summarize potential neuroprotective drugs and therapeutic approaches for these new targets in the treatment of ischemic stroke.

Keywords: Excitotoxicity; Glutamate; Ischemic stroke; NMDA receptor; Neuroprotection.

Publication types

  • Review

MeSH terms

  • Glutamic Acid* / metabolism
  • Humans
  • Ischemic Stroke* / drug therapy
  • Ischemic Stroke* / metabolism
  • Neuroprotective Agents* / pharmacology
  • Neuroprotective Agents* / therapeutic use
  • Receptors, N-Methyl-D-Aspartate / metabolism
  • Stroke / drug therapy
  • Stroke / metabolism

Substances

  • Neuroprotective Agents
  • Receptors, N-Methyl-D-Aspartate
  • Glutamic Acid